{"id":"desferal-deferoxamine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, induration)"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Hearing loss or ototoxicity"},{"rate":null,"effect":"Visual disturbances or retinopathy"},{"rate":null,"effect":"Abdominal pain and diarrhea"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Deferoxamine forms stable complexes with ferric iron (Fe³⁺) and ferrous iron (Fe²⁺), preventing iron from participating in harmful oxidative reactions and tissue damage. The drug-iron complex is readily excreted renally and bilially, effectively reducing total body iron burden. This mechanism is particularly important in conditions of iron overload where excess iron accumulates in organs such as the heart, liver, and endocrine glands.","oneSentence":"Deferoxamine is an iron chelator that binds free iron in the body and facilitates its excretion through urine and feces.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:23.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic iron overload due to repeated blood transfusions (transfusional hemosiderosis)"},{"name":"Iron overload in patients with thalassemia major"},{"name":"Acute iron poisoning"}]},"trialDetails":[{"nctId":"NCT06650163","phase":"PHASE1","title":"Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-05","conditions":"Glioma, Malignant Brain Neoplasm, Meningioma","enrollment":20},{"nctId":"NCT05371132","phase":"PHASE1","title":"Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-20","conditions":"Metastatic Malignant Solid Neoplasm, Lymphoma","enrollment":10},{"nctId":"NCT04566991","phase":"PHASE2","title":"Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)","status":"RECRUITING","sponsor":"Aditya S. Pandey, MD","startDate":"2022-03-20","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":120},{"nctId":"NCT07023666","phase":"PHASE2","title":"Early Screening and Treatment of Heart Complication in Sickle Cell Disease","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-10-07","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT07162363","phase":"PHASE2, PHASE3","title":"Synergistic Minimally Invasive Surgery and Deferoxamine in ICH","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-03-01","conditions":"Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage","enrollment":240},{"nctId":"NCT06763055","phase":"PHASE3","title":"The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-02-27","conditions":"Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage","enrollment":2000},{"nctId":"NCT06204237","phase":"EARLY_PHASE1","title":"Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2024-02-01","conditions":"Peripheral Arterial Occlusive Disease, Critical Limb Ischemia","enrollment":10},{"nctId":"NCT06750419","phase":"PHASE3","title":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-11-06","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":82},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT00749515","phase":"PHASE4","title":"Pilot Study for Patients With Poor Response to Deferasirox","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2008-03","conditions":"Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease","enrollment":15},{"nctId":"NCT02875262","phase":"PHASE1, PHASE2","title":"Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-12-02","conditions":"Intracranial Aneurysm, Subarachnoid Hemorrhage","enrollment":40},{"nctId":"NCT00000588","phase":"PHASE2","title":"Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"1989-06-05","conditions":"Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases","enrollment":120},{"nctId":"NCT03085771","phase":"PHASE2","title":"Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2017-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT03137966","phase":"PHASE2","title":"Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers","status":"NOT_YET_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2022-12-30","conditions":"Diabetic Foot Ulcer","enrollment":174},{"nctId":"NCT00110266","phase":"PHASE2","title":"Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-07-25","conditions":"Myelodysplastic Syndrome, Iron Overload","enrollment":176},{"nctId":"NCT00901199","phase":"PHASE2","title":"Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload","status":"COMPLETED","sponsor":"Elliott Vichinsky","startDate":"2007-09","conditions":"Thalassemia, Iron Overload","enrollment":22},{"nctId":"NCT00447694","phase":"PHASE2","title":"Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02","conditions":"Beta-thalassemia, Iron Overload","enrollment":30},{"nctId":"NCT04361032","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia","status":"UNKNOWN","sponsor":"Abderrahmane Mami Hospital","startDate":"2020-09-04","conditions":"COVID19, Intensive Care Unit","enrollment":260},{"nctId":"NCT04389801","phase":"PHASE4","title":"Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection","status":"UNKNOWN","sponsor":"Hesham Al-Inany","startDate":"2020-06-01","conditions":"Covid 19","enrollment":200},{"nctId":"NCT04333550","phase":"PHASE1, PHASE2","title":"Application of Desferal to Treat COVID-19","status":"UNKNOWN","sponsor":"Kermanshah University of Medical Sciences","startDate":"2020-04","conditions":"COVID-19","enrollment":50},{"nctId":"NCT00001203","phase":"","title":"Deferoxamine for the Treatment of Hemochromatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1985-04-22","conditions":"Diabetes Mellitus, Heart Disease, Hemochromatosis","enrollment":151},{"nctId":"NCT01459718","phase":"PHASE2","title":"Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload","enrollment":32},{"nctId":"NCT01662895","phase":"PHASE2","title":"High-Dose Deferoxamine in Intracerebral Hemorrhage","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2013-03-18","conditions":"Intracerebral Hemorrhage","enrollment":42},{"nctId":"NCT02175225","phase":"PHASE2","title":"Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-10","conditions":"Intracerebral Hemorrhage","enrollment":294},{"nctId":"NCT00598572","phase":"PHASE1","title":"Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-07","conditions":"Intracerebral Hemorrhage","enrollment":20},{"nctId":"NCT02065492","phase":"PHASE2, PHASE3","title":"Amlodipine for Myocardial Iron in Thalassemia","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-02","conditions":"Thalassemia","enrollment":20},{"nctId":"NCT00105495","phase":"PHASE4","title":"Efficacy Study in Removing Excess Iron From the Heart","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2002-12","conditions":"Thalassemia Major, Hemosiderosis","enrollment":60},{"nctId":"NCT02216513","phase":"EARLY_PHASE1","title":"Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2014-09","conditions":"Subarachnoid Hemorrhage","enrollment":2},{"nctId":"NCT02367248","phase":"PHASE1, PHASE2","title":"Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2015-03","conditions":"Intracerebral Hemorrhage","enrollment":180},{"nctId":"NCT01365104","phase":"EARLY_PHASE1","title":"Modulation of Cerebral Blood Flow Using Iron Chelators","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-03","conditions":"Stroke, Problem of Aging","enrollment":97},{"nctId":"NCT01996683","phase":"NA","title":"Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-11","conditions":"Beta-thalassemia, Serum Ferritin, Iron Chelation Therapy","enrollment":50},{"nctId":"NCT00000595","phase":"PHASE2","title":"Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1978-01","conditions":"Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases","enrollment":""},{"nctId":"NCT00658411","phase":"NA","title":"Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT01752153","phase":"PHASE1","title":"Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2012-06","conditions":"Immune Abnormalities","enrollment":25},{"nctId":"NCT00350662","phase":"PHASE3","title":"Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients","status":"COMPLETED","sponsor":"Lipomed","startDate":"2002-01","conditions":"Hemochromatosis","enrollment":95},{"nctId":"NCT00293098","phase":"","title":"Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Children's Hospital of Philadelphia","startDate":"2006-03","conditions":"Iron Overload","enrollment":""},{"nctId":"NCT01511848","phase":"PHASE2, PHASE3","title":"Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-02","conditions":"Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis","enrollment":60},{"nctId":"NCT00349453","phase":"PHASE2","title":"Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients","status":"COMPLETED","sponsor":"Lipomed","startDate":"2005-03","conditions":"Hemochromatosis","enrollment":24},{"nctId":"NCT01369719","phase":"NA","title":"Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload","status":"COMPLETED","sponsor":"Hormozgan University of Medical Sciences","startDate":"2010-02","conditions":"Thalassemia, Iron Overload, Transfusion Related Complications","enrollment":138},{"nctId":"NCT00738413","phase":"PHASE1, PHASE2","title":"Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both","status":"UNKNOWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-08","conditions":"Thalassemia","enrollment":6},{"nctId":"NCT00999349","phase":"PHASE2, PHASE3","title":"Therapeutic Effects of Silymarin in Patients With B-thalassemia Major","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2009-03","conditions":"Beta-thalassemia Major, Iron Overload","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Desferal (deferoxamine)","genericName":"Desferal (deferoxamine)","companyName":"ApoPharma","companyId":"apopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desferal (deferoxamine) is a medication used to treat conditions such as Sickle Cell Disease, Intracerebral Hemorrhage, Anemia (Iron-Loading), Beta-Thalassemia, and Hematologic Diseases. It works by binding to iron in the body, but the exact mechanism of action is unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}